English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT04256317 /

ASTX030-01

A Multi-Phase, Dose-Escalation Followed By An Open-Label, Randomized, Crossover Study Of Oral ASTX030 (Cedazuridine And Azacitidine Given In Combination) Versus Subcutaneous Azacitidine In Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Or Acute Myeloid Leukemia (AML)

DISEASE GROUP:
Leukemia
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: